Stivarga is the standard third-line treatment for metastatic colorectal cancer, gastrointestinal stromal tumors, and hepatocellular carcinoma
Fenebrutinib targets cells in the immune system known as B cells and microglia
Enzomenib, an oral, small-molecule inhibitor designed to disrupt the menin-MLL protein interaction involved in leukemogenesis
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
Approval based on pivotal KOMET Phase III trial demonstrating significant tumour reduction in adults with NF1
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
The combination is approved for advanced endometrial carcinoma that is pMMR or not MSI-H and has progressed after prior systemic therapy
The SELECT-SWITCH study, first head-to-head Phase 3b/4 trial, compared switching to Rinvoq versus switching to another TNF inhibitor
Treatment with TUKYSA was well-tolerated, with a safety profile consistent with previously known profiles of the individual agents
Subscribe To Our Newsletter & Stay Updated
